Immunomonitoring measures in relapsing-remitting multiple sclerosis

被引:11
|
作者
Matsui, M [1 ]
Araya, S
Wang, HY
Matsushima, K
Saida, T
机构
[1] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Ctr, Ukyo Ku, Kyoto 6168255, Japan
[2] Natl Utano Hosp, Dept Neurol, Ukyo Ku, Kyoto 6168255, Japan
[3] Univ Tokyo, Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan
关键词
multiple sclerosis; flow cytometry; cytokine; surface antigen;
D O I
10.1016/j.jneuroim.2003.11.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared with stable stage patients and 16 healthy controls. CCR4(+) Th2 cells were persistently decreased at every MS stage as compared to the controls. CD4(+)CD29(+) and CD4(+)CXCR3(+) cells were closely correlated with IFN-gamma-producing cells. These findings suggest that simultaneous flow cytometry for these two types of measurements can provide information concerning current immune status in MS. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:192 / 199
页数:8
相关论文
共 50 条
  • [31] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [32] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [33] Cognitive Impairment In Relapsing-Remitting Multiple Sclerosis
    Topcular, Baris
    Ozcan, M. Emin
    Kurt, Elif
    Kuscu, Demet Yandim
    Icen, Nilufer Kale
    Sutlas, Pakize Nevin
    Kirbas, Dursun
    Bingol, Ayhan
    [J]. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (03): : 178 - 182
  • [34] Intravenous immunoglobulin in relapsing-remitting multiple sclerosis
    Achiron, A
    Barak, Y
    SarovaPinhas, I
    Achiron, R
    Gabbay, U
    Rotstein, Z
    Noy, S
    [J]. INTRAVENOUS IMMUNOGLOBULIN: RESEARCH AND THERAPY, 1996, : 289 - 293
  • [35] Development of laquinimod for relapsing-remitting multiple sclerosis
    Jeffery, Douglas R.
    [J]. FUTURE NEUROLOGY, 2008, 3 (06) : 641 - 648
  • [36] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [37] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [38] Thalamic neurodegeneration in relapsing-remitting multiple sclerosis
    Wylezinska, M
    Cifelli, A
    Jezzard, P
    Palace, J
    Alecci, M
    Matthews, PM
    [J]. NEUROLOGY, 2003, 60 (12) : 1949 - 1954
  • [39] Postural Control in Relapsing-Remitting Multiple Sclerosis
    Cusin, Flavia Salvaterra
    Tomaz, Andreza
    Gananca, Mauricio Malavasi
    Oliveira, Enedina Maria
    Falcao Goncalves, Alessandra Billi
    Caovilla, Heloisa Helena
    [J]. INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2022, 26 (04) : 592 - 604
  • [40] Disability trajectories in relapsing-remitting multiple sclerosis
    Uher, T.
    Horakova, D.
    Havrdova, E. Kubala
    Izquierdo, G.
    Eichau, S.
    Patti, F.
    Prat, A. P.
    Girard, M.
    Duquette, P.
    Grammond, P.
    Onofrj, M.
    Lugaresi, A. L.
    Bergamaschi, R.
    Ozakbas, S.
    Grand'Maison, F.
    Hupperts, R.
    Sola, P.
    Ferraro, D.
    Sa, M. J.
    Kalincik, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 813 - 814